1. Metabolic Enzyme/Protease
  2. HIF/HIF Prolyl-Hydroxylase

HIF/HIF Prolyl-Hydroxylase

HIFs (Hypoxia-inducible factors) are transcription factors that respond to changes in available oxygen in the cellular environment, to be specific, to decreases in oxygen, or hypoxia. The HIF signaling cascade mediates the effects of hypoxia, the state of low oxygen concentration, on the cell. Hypoxia often keeps cells from differentiating. However, hypoxia promotes the formation of blood vessels, and is important for the formation of a vascular system in embryos, and cancer tumors. The hypoxia in wounds also promotes the migration of keratinocytes and the restoration of the epithelium. In general, HIFs are vital to development. In mammals, deletion of the HIF-1 genes results in perinatal death. HIF-1 has been shown to be vital to chondrocyte survival, allowing the cells to adapt to low-oxygen conditions within the growth plates of bones. HIF plays a central role in the regulation of human metabolism. Recently, several drugs that act as selective HIF prolyl-hydroxylase inhibitors have been developed.

HIF/HIF Prolyl-Hydroxylase Related Products (35):

Cat. No. Product Name Effect Purity
  • HY-12867
    PT-2385 Antagonist 99.48%
    PT-2385 is a novel and selective HIF-2α antagonist with ITC Binding Affinity (Kd) of <50 nM.
  • HY-15893
    DMOG Inhibitor 99.15%
    DMOG is an inhibitor of HIF prolyl hydroxylase and an antagonist of α-ketoglutarate cofactor.
  • HY-13426
    FG-4592 Inhibitor 99.91%
    FG-4592 is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, currently used for the treatment of anemia.
  • HY-10231
    PX-478 Inhibitor >98.0%
    PX-478 is an inhibitor of hypoxia-inducible factor-1α (HIF-1α), and is cytotoxic to a variety of cancer cell lines under normoxia and hypoxia in vitro with IC50 of 20-30 μM.
  • HY-17608
    Daprodustat Inhibitor 99.95%
    Daprodustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treatment of anemia associated with chronic kidney disease.
  • HY-16031
    AFP464 Inhibitor
    AFP464, is an active HIF-1α inhibitor with an IC50 of 0.25 μM, also is a potent aryl hydrocarbon receptor (AhR) activator.
  • HY-109057
    Enarodustat Inhibitor
    Enarodustat is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM; Enarodustat has entered clinical trial for renal anemia.
  • HY-12033
    2-Methoxyestradiol Inhibitor 99.54%
    2-Methoxyestradiol is a microtubule and HIF-1 inhibitor, binds to tubulin at or near the colchicine site and inhibits the polymerization of tubulin in vitro, works by interfering with normal microtubule function.
  • HY-101277
    Vadadustat Inhibitor 98.02%
    Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.
  • HY-15836
    BAY 87-2243 Inhibitor 99.41%
    BAY 87-2243 is a highly potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor.
  • HY-12519
    Oltipraz Inhibitor 99.15%
    Oltipraz has an inhibitory effect on HIF-1α activation by insulin in a time-dependent manner, completely abrogating HIF-1α induction at ≥10 μM concentrations, the IC50 of Oltipraz for HIF-1α inhibition is 10 μM.
  • HY-N0055
    Chlorogenic acid Inhibitor 99.29%
    Chlorogenic acid(NSC-407296; 3-O-Caffeoylquinic acid) is one of the most abundant polyphenols in the human diet, has been reported to inhibit cancer cell growth and a major anti-inflammatory constituent of lonicerae flos extract.
  • HY-15468
    IOX2 Inhibitor 98.41%
    IOX2 is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC50 of 22 nM.
  • HY-12654
    Molidustat Inhibitor 98.33%
    Molidustat (BAY 85-3934) is a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with mean IC50 values of 480 nM for PHD1, 280 nM for PHD2, and 450 nM for PHD3.
  • HY-N0293
    Paeoniflorin Inhibitor >98.0%
    Paeoniflorin is a herbal constituent extracted from the root of Paeonia albiflora Pall.
  • HY-13671
    LW6 Inhibitor >98.0%
    LW6 is a novel HIF-1 inhibitor with an IC50 of 4.4 μM.
  • HY-N0560
    Oroxylin A Inhibitor 99.63%
    Oroxylin A is a natural active flavonoid with strong anticancer effects.
  • HY-18777
    KC7F2 Inhibitor 99.61%
    KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study.
  • HY-100575
    Acriflavine Inhibitor >98.0%
    Acriflavine is a fluorescent dye for labeling high molecular weight RNA. It is also a topical antiseptic.
  • HY-12832
    JNJ-42041935 Inhibitor 99.79%
    JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD; inhibits PHD1, PHD2, and PHD3 with pKi values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.